Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN5A | Q14524 | 5/20 | 0.58 |
| ▸ | MAOA | P21397 | 1/20 | 0.48 |
| ▸ | MAOB | P27338 | 1/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.44 |
| ▸ | PIM1 | P11309 | 8/20 | 0.37 |
| ▸ | PIM2 | Q9P1W9 | 7/20 | 0.37 |
| ▸ | FLT3 | P36888 | 1/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.36 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.36 |
| ▸ | PDE10A | Q9Y233 | 2/20 | 0.35 |
| ▸ | PDE2A | O00408 | 1/20 | 0.35 |
| ▸ | PDE7A | Q13946 | 1/20 | 0.35 |
| ▸ | PDE11A | Q9HCR9 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20191052 | 0.87 | SCN5A (0.50) | SCN5AMAOAMAOBPIM1PIM2 | |
| SCHEMBL20189286 | 0.86 | SCN5A (0.67) | SCN5AMAOAMAOBCYP1A2PIM1 | |
| SCHEMBL20190458 | 0.84 | CYP1A2 (0.48) | SCN5AMAOAMAOBCYP1A2PIM1 | |
| SCHEMBL20190535 | 0.81 | SCN5A (0.73) | SCN5AMAOAMAOBCYP1A2PIM1 | |
| SCHEMBL20190211 | 0.78 | CYP1A2 (0.47) | SCN5AMAOAMAOBCYP1A2KCNH2 | |
| SCHEMBL20189738 | 0.78 | SCN5A (0.65) | SCN5AMAOAMAOBCYP1A2MCHR1 | |
| SCHEMBL20190880 | 0.77 | SCN5A (0.58) | SCN5APIM1PIM2FLT3 | |
| SCHEMBL23572415 | 0.73 | SCN5A (1.00) | SCN5AMAOAMAOBCYP1A2 | |
| SCHEMBL20190080 | 0.73 | SCN5A (0.65) | SCN5AMAOAMAOBPIM1PIM2 | |
| SCHEMBL20190843 | 0.71 | SCN5A (0.61) | SCN5AMAOAMAOBCYP1A2PIM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210188839-A1 | COMPOUNDS AND THEIR METHODS OF USE | PRAXIS PRECISION MEDICINES, INC. | 2021-06-24 | — | — | US | disclosed |
| US-20210188839-A1 | COMPOUNDS AND THEIR METHODS OF USE | PRAXIS PRECISION MEDICINES, INC. | 2021-06-24 | — | — | US | disclosed |
| WO-2018098500-A1 | COMPOUNDS AND THEIR METHODS OF USE | PRAXIS PRECISION MEDICINES, INC. (US) | 2018-05-31 | — | — | WO | disclosed |
| WO-2018098500-A1 | COMPOUNDS AND THEIR METHODS OF USE | PRAXIS PRECISION MEDICINES, INC. (US) | 2018-05-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210188839-A1 | COMPOUNDS AND THEIR METHODS OF USE | SCN1A, SCN3A, SCN1B | SCN5A 8/4885MAOA 1799/4885MAOB 1870/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.